Morgan Stanley Schedule 13G passive stakes

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have disclosed beneficial ownership of 7.4% of Sage Therapeutics, Inc.'s common stock as of December 31, 2024.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have reported a reduction in their beneficial ownership of Brookfield Real Assets Income Fund Inc. common stock to 4.4%, falling below the 5% threshold.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have filed an amended Schedule 13G disclosing a 13.0% beneficial ownership stake in Western Asset Premier Bond Fund as of December 31, 2024.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed beneficial ownership of 6.2% of Praxis Precision Medicines, Inc.'s common stock as of December 31, 2024.

Morgan Stanley has filed an amended Schedule 13G, reporting that its beneficial ownership in UroGen Pharma Ltd. has fallen to 1.8%, below the 5% reporting threshold.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have disclosed a beneficial ownership of 6.9% in Galaxy Next Generation, Inc., totaling 4,836,001 shares of common stock as of December 31, 2024.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have disclosed an 8.9% beneficial ownership stake in Tortoise Energy Infrastructure Corp. as of December 31, 2024.

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have disclosed beneficial ownership of 6.3% of Syndax Pharmaceuticals Inc.'s common stock as of December 31, 2024.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed a beneficial ownership of 5.6% in ATRenew Inc.'s Class A Ordinary Shares as of December 31, 2024.

Morgan Stanley has filed an amended Schedule 13G, indicating it is no longer a beneficial owner of more than five percent of RCM Technologies Inc.'s common stock.

Morgan Stanley and its subsidiary, Parametric Portfolio Associates LLC, have jointly disclosed a beneficial ownership of 8.7% in RiverNorth/DoubleLine Strategic Opportunity Fund, Inc., as detailed in their latest Schedule 13G amendment.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have reported a reduction in their beneficial ownership of Nuveen Variable Rate Preferred & Income Fund to 2.5%, falling below the 5% threshold.

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have filed a Schedule 13G disclosing a passive beneficial ownership of 6.0% in Marinus Pharmaceuticals, Inc. as of December 31, 2024.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have filed an amended Schedule 13G disclosing a 16.0% beneficial ownership stake in Key Tronic Corp as of December 31, 2024.

Morgan Stanley and its subsidiary, Parametric Portfolio Associates LLC, have reported a reduction in their beneficial ownership of Nuveen Real Asset Income & Growth Fund's common stock to 4.9%, falling below the 5% threshold.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have disclosed a 7.3% beneficial ownership stake in Guggenheim Active Allocation Fund as of December 31, 2024.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have filed an updated Schedule 13G, confirming a 7.9% beneficial ownership stake in Clough Global Equity Fund.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed beneficial ownership of 7.5% of Kornit Digital Ltd.'s Ordinary Shares as of December 31, 2024.

Morgan Stanley and its wholly-owned subsidiary, Parametric Portfolio Associates LLC, have jointly disclosed a beneficial ownership of 7.3% in Nuveen Core Plus Impact Fund, totaling 2,109,660 common shares.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed a combined beneficial ownership of 8.3% of NeuroPace Inc.'s common stock as of December 31, 2024.

Morgan Stanley and its wholly-owned subsidiary, Parametric Portfolio Associates LLC, have jointly disclosed a beneficial ownership of 5.0% in Nuveen Variable Rate Preferred & Income Fund.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have disclosed a beneficial ownership of 7.1% in BlackRock MuniHoldings Quality Fund II, Inc., totaling 1,561,355 common shares as of December 31, 2024.

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have disclosed a combined beneficial ownership of 7.6% of Samsara Inc.'s Class A Common Stock as of December 31, 2024.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed an amended Schedule 13G, detailing their beneficial ownership of 7.5% of Pulmonx Corp's common stock as of December 31, 2024.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have disclosed a 5.8% beneficial ownership stake in Western Asset High Income Opportunity Fund Inc., holding 5,482,889 common shares as of December 31, 2024.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed beneficial ownership of 6.6% of Lesaka Technologies Inc.'s common stock as of December 31, 2024.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have disclosed a 5.6% beneficial ownership stake in Clough Global Opportunities Fund, held in the ordinary course of business.

Morgan Stanley has filed a Schedule 13G, revealing a passive beneficial ownership of 5.8% in Jack Henry & Associates Inc. as of December 31, 2024.

Morgan Stanley has filed an amended Schedule 13G, indicating its beneficial ownership in E2open Parent Holdings, Inc. has fallen to 2.4% as of December 31, 2024, below the 5% reporting threshold.

Morgan Stanley and its subsidiary, Morgan Stanley Smith Barney LLC, have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 9.6% in Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust as of December 31, 2024.